Pliant Therapeutics price target raised to $52 from $50 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Pliant Therapeutics to $52 from $50 and keeps a Buy rating on the shares following top-line results from the placebo-controlled Phase 2a INTEGRIS-PSC study of bexotegrast across three dose groups in patients with primary sclerosing cholangitis and suspected moderate-to-severe liver fibrosis. The readout “did not disappoint in any way,” the analyst tells investors in a research note.